None listed
Conditions
Brief summary
In this prospective single-centre study, patients with recurrent UTIs and/ or catheter blockages were prescribed patient- or carer-administered intravesical gentamicin, nocte, for 6 months, as prophylaxis. The hypothesis was that intravesical gentamicin would decrease rates of UTIs, and potentially also decrease rates of catheter blockages. Compared with pre-treatment, patients on prophylaxis experienced significantly fewer subjective and objective UTIs per 12-month-equivalent. Intravesical gentamicin appears safe and effective prophylaxis for recurrent UTIs.
Interventions
Patient- or carer-administered 30mL of 0.48mg/mL gentamicin solution, intravesical, with solution retention in bladder for 60mins, once in the evening, for six months, as prophylaxis for recurrent urinary tract infection.
Adherence to intervention was assessed with telephone consults every two months.
Sponsors
University of Calgary
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Prevention
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Eligible patients were adults with any form of bladder drainage (spontaneous voiding, clean intermittent catheterisation (CIC), indwelling urethral catheters [IUC] or suprapubic catheters [SPC]) with either recurrent UTIs failing low dose oral prophylaxis (antibiotic or non-antibiotic) and/ or frequent catheter blockages, who received >=14 consecutive days’ once daily intravesical gentamicin in period 01/06/2024 – 01/04/2025, and provided written study consent. A minimum of 14 days’ prophylaxis was selected to mirror criteria of previous studies. Recurrent UTIs were defined as >=2 UTIs in six months or >=3 in twelve months. Frequent catheter blockages were defined as those flagged as bothersome per patient report.
Exclusion criteria
Patients who did not complete 14 days’ prophylaxis.
Outcome results
None listed